Results of Comparative Study Between Epigenomics AG Epi proColon® and FIT to be Presented at Digestive Disease Week
5/15/2013 9:29:53 AM
More...
|
Epigenomics AG Announces Q1 2013 Financial Results and Reports on Operational Highlights
5/8/2013 9:46:25 AM
More...
|
Epigenomics AG: Dr. Uwe Staub Appointed to the Executive Board
4/3/2013 9:49:03 AM
More...
|
Epigenomics AG Reports Results for the Financial Year Ended 31 December 2012
3/21/2013 12:42:05 PM
More...
|
Epigenomics AG Signs Licensing Agreement With Biochain Institute, Inc. for Septin9 in China
3/7/2013 11:10:20 AM
More...
|
Epigenomics AG Receives Notification of Priority Review Status and Acceptance for Filing by FDA of PMA Application for Epi proColon®
2/21/2013 10:38:41 AM
More...
|
Predictive Biosciences Launches Prostate Cancer Test Based on Epigenomics AG's DNA Methylation Marker
1/29/2013 10:37:57 AM
More...
|
Epigenomics AG Submits the Fourth Module and Completes Its PMA Submission to the FDA for Epi proColon®
1/7/2013 11:39:04 AM
More...
|
Epigenomics AG Provides Additional Data on the Outcome of its Head-to-Head Comparison Study of Epi proColon® to FIT
12/19/2012 11:31:53 AM
More...
|
Epigenomics AG Reports Non-Inferiority of Blood-Based Epi proColon® Against Fecal Immunochemical Testing in Detection of Colorectal Cancer in a Head-to-Head Comparative Study
12/4/2012 12:19:02 PM
More...
|
|